Vitra Labs

Revolutionizing In Vitro Fertilization

Infertility is a growing **epidemic**
In Vitro Fertilization is **costly** and **ineffective**

1 in 6 people struggle with infertility

~180m people worldwide

~4M IVF cycles globally

3+ cycles on average, 75% cash pay

~$60K cost of successful pregnancy

Our mission: to provide women with alternative options to hormone induced oocyte retrieval

Patient iPSC-derived oocytes enable:

- Generation of 100X more oocytes/cycle, pre-implantation genetic testing, increased IVF efficiency, increased patient pool

Platform: precise and temporal control over signal pathway activation and maintenance for optimization of iPSC differentiations

Protocol: proof of concept in fastest, cheapest, and most efficient method of generating oocyte precursors.

Provisional Patent Application: US 2020/PRV3730194



IVANA VASIC
PhD Candidate, UCSF
Research focus: stem cell biology, bioinformatics, germ cell differentiation

LEXI HENKEL
MBA Candidate, Stanford GSB
Member of founding team at TMRW
Life Sciences, Finance and Strategy